BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $14.96B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 2.81M
Average 2.49M
BBIO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
BridgeBio Pharma, Inc.NASDAQ: BBIO
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$141.56M, compared with -$142.7M a year earlier. Trailing-twelve-month EBITDA was -$611.26M.
Context
- EBITDA amounted to 134.7% of revenue in FY2025, down 62.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 13 analysts of -$356.18M (+47.3%) for the fiscal year ending Dec 2026, a step up from the -54.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$141.56M-25.8% QoQ
- Last fiscal yearDec 2025
- -$676.45M-54.9% YoY
- LTMJun 2026
- -$611.26M+5.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.8% | +71.3% | +70.5 pp |
| 1 year | -54.9% | +47.3% | +102.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (676.45M) USD
- Year-over-year change
- -54.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (676.45M) | -54.9% |
| FY2024 | 2024-12-31 | (436.83M) | +22.7% |
| FY2023 | 2023-12-31 | (565.47M) | -42.3% |
| FY2022 | 2022-12-31 | (397.44M) | +25.5% |
| FY2021 | 2021-12-31 | (533.83M) | — |
EBITDA vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.0% is the 3rd highest of 11, against a peer median of -46.7%.
- EBITDA amounts to 85.7% of revenue for BBIO, versus a peer median of 36.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.15B USD | +773.6% | — | 24.0% | |
| LTM Sep 2026 | €259.93M EUR | +295.2% | — | 21.5% | |
| LTM Jun 2026 | $173.52M USD | -79.4% | — | 17.2% | |
| LTM Sep 2026 | -$106.58M USD | -372.0% | — | 16.4% | |
| LTM Mar 2026 | -$119.51M USD | -312.9% | — | 597.6% | |
| LTM Sep 2026 | -$398.31M USD | -14.0% | — | 69878.4% | |
| LTM Sep 2026 | -$473.54M USD | -208.3% | — | 49.3% | |
| LTM Jun 2026 | -$498.21M USD | -6.5% | — | 13823.7% | |
| LTM Mar 2026 | -$503.35M USD | -11.9% | — | 75.2% | |
| LTM Jun 2026 | -$611.26M USD | +5.0% | — | 85.7% | |
| LTM Sep 2026 | -$81.69B USD | -10676.6% | +29.2% | 8.0% | |
| Peer median (excluding BBIO) | — | -46.7% | +29.2% | 36.6% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$76.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.